779 related articles for article (PubMed ID: 35176090)
1. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.
Mittal A; Khattri A; Verma V
PLoS Pathog; 2022 Feb; 18(2):e1010260. PubMed ID: 35176090
[TBL] [Abstract][Full Text] [Related]
2. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
[TBL] [Abstract][Full Text] [Related]
4. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
5. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.
Niu L; Wittrock KN; Clabaugh GC; Srivastava V; Cho MW
Front Immunol; 2021; 12():647934. PubMed ID: 33995366
[TBL] [Abstract][Full Text] [Related]
6. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
[TBL] [Abstract][Full Text] [Related]
7. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
8. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
10. Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
Ishimaru H; Nishimura M; Shigematsu H; Marini MI; Hasegawa N; Takamiya R; Iwata S; Mori Y
J Virol; 2024 May; 98(5):e0041624. PubMed ID: 38624232
[TBL] [Abstract][Full Text] [Related]
11. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
[TBL] [Abstract][Full Text] [Related]
12. The effect of spike mutations on SARS-CoV-2 neutralization.
Rees-Spear C; Muir L; Griffith SA; Heaney J; Aldon Y; Snitselaar JL; Thomas P; Graham C; Seow J; Lee N; Rosa A; Roustan C; Houlihan CF; Sanders RW; Gupta RK; Cherepanov P; Stauss HJ; Nastouli E; ; Doores KJ; van Gils MJ; McCoy LE
Cell Rep; 2021 Mar; 34(12):108890. PubMed ID: 33713594
[TBL] [Abstract][Full Text] [Related]
13. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
Lin WS; Chen IC; Chen HC; Lee YC; Wu SC
Front Immunol; 2021; 12():795741. PubMed ID: 34925381
[TBL] [Abstract][Full Text] [Related]
14. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
[TBL] [Abstract][Full Text] [Related]
15. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.
Schmidt F; Weisblum Y; Rutkowska M; Poston D; DaSilva J; Zhang F; Bednarski E; Cho A; Schaefer-Babajew DJ; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Nature; 2021 Dec; 600(7889):512-516. PubMed ID: 34544114
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
Starr TN; Czudnochowski N; Liu Z; Zatta F; Park YJ; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Tortorici MA; Walls AC; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Dillen JR; Tucker H; Bassi J; Silacci-Fregni C; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Abdelnabi R; Foo SC; Cameroni E; Stumpf S; Croll TI; Nix JC; Havenar-Daughton C; Piccoli L; Benigni F; Neyts J; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Virgin HW; Whelan SPJ; Veesler D; Corti D; Bloom JD; Snell G
Nature; 2021 Sep; 597(7874):97-102. PubMed ID: 34261126
[TBL] [Abstract][Full Text] [Related]
17. An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants.
Miller NL; Clark T; Raman R; Sasisekharan R
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696440
[TBL] [Abstract][Full Text] [Related]
18. Evolving threat.
Kupferschmidt K
Science; 2021 Aug; 373(6557):844-849. PubMed ID: 34413220
[No Abstract] [Full Text] [Related]
19. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.
Liu Z; VanBlargan LA; Bloyet LM; Rothlauf PW; Chen RE; Stumpf S; Zhao H; Errico JM; Theel ES; Liebeskind MJ; Alford B; Buchser WJ; Ellebedy AH; Fremont DH; Diamond MS; Whelan SPJ
Cell Host Microbe; 2021 Mar; 29(3):477-488.e4. PubMed ID: 33535027
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
